$ARGX
AI 分析生成于 May 11, 2026
AI Score
Hold$ARGX
argenx SE
$ARGXNASDAQHealthcareLarge-Cap
argenx develops antibody-based therapies for autoimmune diseases with lead product Vyvgart for myasthenia gravis.
Market Cap
$32.0B
Revenue (TTM)
$2.5B
+85.0%
Net Income (TTM)
$0.2B
N/A
EPS (TTM)
$3.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$350-$630
Beta
0.72
Dimension Scores
Fundamental
62Technical
68Sentiment
78Risk / Reward
60Momentum
82Financial Health
Profitability
67moderate
Growth
85strong
Liquidity
68strong
Solvency
64strong
Efficiency
60moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $ARGX
Free · No credit card required
免责声明: AI 生成的分析仅供教育参考,不构成投资建议。请始终咨询合格的理财顾问。